# PRG S&Tech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prg-s-tech

- Industry: Pharmaceuticals
- Headquarters: Busan, South Korea
- Website: www.prgst.com/
- Total disclosed funding: $15M
- Latest round: Series B (Jan 14, 2021)
- Investors on record: 7

## About

Based in South Korea, PRG S&Tech Inc. specializes in the development and commercialization of innovative therapeutic solutions for rare genetic disorders, aiming to enhance patient care and treatment outcomes. Founded in 2017, PRG S&Tech Inc. focuses on delivering advanced therapeutic products for rare genetic disorders. In May 2026, PRG S&Tech Inc. raised KRW 20 billion in pre-IPO funding from new investors SL Investment, S Ventures, KDB Capital, K & Investment Partners, Sneak Peek Investment, J1 Venture Capital, Hanyang Securities, and Yuanta Securities Korea, Returning investors KNet Investment Partners, BNK Venture Capital, and Union Investment Partners also participated in the round. PRG S&Tech is headquartered in South Korea and has a strategic emphasis on expanding its research and therapeutic offerings in the biotechnology sector. 

PRG S&Tech Inc. specializes in the development and commercialization of innovative solutions for rare genetic disorders. The company's core offerings include advanced therapeutic products aimed at addressing unmet medical needs, particularly in the field of genetic diseases. These products are designed to provide tailored solutions that improve patient outcomes and quality of life. PRG S&Tech serves a diverse clientele that includes healthcare providers, research institutions, and pharmaceutical companies, focusing on both domestic and international markets. Notably, their products are sold in various regions, including Asia and Europe, where the company aims to expand access to their groundbreaking therapies and foster partnerships with local healthcare systems. 

PRG S&Tech generates revenue through a combination of direct sales and strategic partnerships with healthcare institutions and pharmaceutical companies. The company's transaction structure primarily involves B2B relationships, supplying their therapeutic products to hospitals and clinics that treat patients with rare genetic conditions. Additionally, PRG S&Tech may engage in collaborative agreements with research organizations to facilitate further development and distribution of their flagship products. In 2024, PRG S&Tech reported an EBITDA of KRW 4,443,816.90.

## Funding rounds

- Series B, Jan 14, 2021, $10M — Korea Development Bank, Union Investment Partners, BNK Venture Capital, Platinum Technology Investment, KNet Investment Partners
- Series A, May 1, 2019, $4.3M — Korea Development Bank, Platinum Technology Investment
- Seed, Jul 1, 2018 — Korea Tech Incubator for Startup, Korea University Holdings

## Investors

- Korea Tech Incubator for Startup — Seed
- Korea University Holdings (https://capitalatlas.ai/funds/korea-university-holdings) — Seed
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series A, Series B
- Platinum Technology Investment (https://capitalatlas.ai/funds/platinum-technology-investment) — Series A, Series B
- Union Investment Partners (https://capitalatlas.ai/funds/union-investment-partners) — Series B
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series B
- KNet Investment Partners (https://capitalatlas.ai/funds/knet-investment-partners) — Series B